Primary care physicians’ perspectives on the prescription opioid epidemic

Drug and Alcohol Dependence

Volumn 165, Issue , 2016, Pages 61-70

  Kennedy Hendricks, Alene ^a   Busch, Susan H ^b   McGinty, Emma E ^a   Bachhuber, Marcus A ^c   Niederdeppe, Jeff ^d   Gollust, Sarah E ^e   Webster, Daniel W ^a   Fiellin, David A ^f   Barry, Colleen L ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b YALE UNIVERSITY   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d Cornell University ^*  (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Analgesics; Opioid related disorders; Opioids; Physicians; Primary care; Substance related disorders

Indexed keywords

OPIATE;

ARTICLE; CONTROLLED STUDY; EPIDEMIC; FEMALE; GENERAL PRACTITIONER; HEALTH BELIEF; HUMAN; LIKERT SCALE; MALE; OPIATE ADDICTION; PHYSICIAN ATTITUDE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; DRUG OVERDOSE; HEALTH PERSONNEL ATTITUDE; PSYCHOLOGY;

ATTITUDE OF HEALTH PERSONNEL; DRUG OVERDOSE; FEMALE; HUMANS; MALE; OPIOID-RELATED DISORDERS; PHYSICIANS, PRIMARY CARE;

EID: 84973534453     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2016.05.010     Document Type: Article

References (52)

1. Alexander, C.G., Frattaroli, S., Gielen, A.C., The Prescription Opioid Epidemic: An Evidence-Based Approach. 2015, The Johns Hopkins University School of Public Health, Baltimore, MD.
2. American Medical Association (AMA), Issue Brief: Rx Drug Abuse And Diversion. 2013, AMA, Washington, DC.
3. American Psychiatric Association, Diagnostic And Statistical Manual Of Mental Disorders. 5th ed., 2013, APA, Washington, DC.
4. Bachhuber, M.A., McGinty, E.E., Kennedy-Hendricks, A., Niederdeppe, J., Barry, C.L., Messaging to increase public support for naloxone distribution policies in the United States: results from a randomized survey experiment. PLoS One, 10, 2015, e0130050.
5. Barry, C.L., McGinty, E.E., Pescosolido, B.A., Goldman, H.H., Stigma, discrimination, treatment effectiveness, and policy: public views about drug addiction and mental illness. Psychiatr. Serv. 65 (2014), 1269–1272, 10.1176/appi.ps.201400140.
6. Barry, C., Kennedy-Hendricks, A., Gollust, S., Niederdeppe, J., Webster, D., McGinty, B., Understanding Americans’ views on opioid pain reliever abuse. Addiction 111 (2016), 85–93, 10.1111/add.13077.
7. Centers for Disease Control and Prevention (CDC), Policy Impact: Prescription Painkiller Overdoses [WWW Document]. 2013, CDC Natl. Cent. Inj. Prev. Control http://www.cdc.gov/HomeandRecreationalSafety/pdf/PolicyImpact-PrescriptionPainkillerOD.pdf (accessed 04.01.15).
8. Chen, J.H., Humphreys, K., Shah, N.H., Lembke, A., Distribution of opioids by different types of Medicare prescribers. JAMA Intern. Med. 176 (2015), 259–261.
9. Chou, R., Turner, J., Devine, E., Hansen, R., Sullivan, S., Blazine, I., Dana, T., Bougatsos, C., Devo, R., The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann. Intern. Med 162 (2015), 276–286.
10. Cicero, T.J., Ellis, M.S., Surratt, H.L., Kurtz, S.P., The changing face of heroin use in the United States. JAMA Psychiatry 71 (2014), 821–826, 10.1001/jamapsychiatry.2014.366.
11. Compton, W.M., Jones, C.M., Baldwin, G.T., Relationship between nonmedical prescription-opioid use and heroin use. N. Engl. J. Med. 374 (2016), 154–163.
12. Dowell, D., Haegerich, T.M., Chou, R., CDC guideline for prescribing opioids for chronic pain—United States, 2016. MMWR Recomm. Rep. 65 (2016), 1–49.
13. Edlund, M., Martin, B., Russo, J., DeVries, A., Braden, J., Sullivan, M., The role of opioid prescription in incident opioid abuse and dependence among individuals with chronic noncancer pain: the role of opioid prescription. Clin. J. Pain 30 (2014), 557–564.
14. Fiellin, D.A., O'Connor, P., Chawarski, M., Pakes, J., Pantalon, M., Schottenfeld, R., Methadone maintenance in primary care: a randomized controlled trial. JAMA 286 (2001), 1724–1731.
15. Fiellin, D.A., Schottenfeld, R., Cutter, C., Moore, B., Barry, D., O'Connor, P., Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial. JAMA Intern. Med 174 (2014), 1947–1954.
16. Flanigan, T., McFarlane, E., Cook, S., Conducting survey research among physicians and other medical professionals: a review of current literature. ASA Proc. Sect. Surv. Res. Methods, 2008, 4136–4147.
17. Food and Drug Administration (FDA), Pediatric Pain Management Options [WWW Document]. 2015, Cent. Drug Eval. Res. Conversation. FDA website http://www.fda.gov/drugs/newsevents/ucm456973.htm (accessed 11.20.15).
18. GfK KnowledgeNetworks, Physicians Consulting Network (PCN(R) [WWW Document] GfK Website. 2015 http://www.knowledgenetworks.com/resources/pcn.html (accessed 07.15.15).
19. Gilkey, M.B., Malo, T.L., Shah, P.D., Hall, M.E., Brewer, N.T., Quality of physician communication about human papillomavirus vaccine: findings from a national survey. Cancer Epidemiol. Biomark. Prev. 24 (2015), 1673–1679, 10.1158/1055-9965.EPI-15-0326.
20. Gilkey, M.B., Moss, J.L., Coyne-Beasley, T., Hall, M.E., Shaw, P.D., Brewer, N.T., Physician communication about adolescent vaccination: how is human papillomavirus vaccine different?. Prev. Med. 77 (2015), 181–185.
21. Han, B., Compton, W.M., Jones, C.M., Cai, R., Nonmedical prescription opioid use and use disorders among adults aged 18 through 64 years in the United States, 2003–2013. JAMA 314 (2015), 1468–1478.
22. Hwang, C.S., Turner, L.W., Kruszewski, S.P., Kolodny, A., Alexander, G.C., Primary care physicians’ knowledge and attitudes regarding prescription opioid abuse and diversion. Clin. J. Pain, 1, 2015, 10.1097/AJP.0000000000000268.
23. Hwang, C.S., Turner, L.W., Kruszewski, S.P., Kolodny, A., Alexander, G.C., Prescription drug abuse: a national survey of primary care physicians. JAMA Intern. Med., 175, 2015, 302, 10.1001/jamainternmed.2014.6403.Author.
24. Jamison, R., Sheehan, K., Scanlan, E., Matthews, M., Ross, E., Beliefs and attitudes about opioid prescribing and chronic pain management: survey of primary care providers. J. Opioid Manag. 10 (2014), 375–382.
25. Kolodny, A., Courtwright, D.T., Hwang, C.S., Kreiner, P., Eadie, J.L., Clark, T.W., Alexander, G.C., The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. Annu. Rev. Public Health 36 (2015), 1–25, 10.1146/annurev-publhealth-031914-122957.
26. LeResche, L., Saunders, K., Dublin, S., Thielke, S., Merrill, J.O., Shortreed, S.M., Campbell, C., Von Korff, M.R., Sex and age differences in global pain status among patients using opioids long term for chronic noncancer pain. J. Women's Health 24 (2015), 629–635.
27. Levy, B., Paulozzi, L., Mack, K.A., Jones, C.M., Trends in opioid analgesic-prescribing rates by specialty, U.S. Am. J. Prev. Med. 49 (2015), 409–413.
28. Link, B.G., Yang, L.H., Phelan, J.C., Collins, P.Y., Measuring mental illness stigma. Schizophr. Bull. 30 (2004), 511–541, 10.1093/oxfordjournals.schbul.a007098.
29. Livingston, J.D., Milne, T., Fang, M.L., Amari, E., The effectiveness of interventions for reducing stigma related to substance use disorders: a systematic review. Addiction 107 (2012), 39–50, 10.1111/j.1360-0443.2011.03601.x.
30. Macerollo, A., Mack, D., Oza, R., Bennett, I., Wallace, L., Academic family medicine physicians’ confidence and comfort with opioid analgesic prescribing for patients with chronic nonmalignant pain. J. Opioid Manage. 10 (2014), 255–261.
31. Mattick, R., Breen, C., Kimber, J., Davoli, M., Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst. Rev., 2009, 10.1002/14651858.cd002209.pub2 (CD002209).
32. Mattick, R., Breen, C., Kimber, J., Davoli, M., Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst. Rev., 2014, 10.1002/14651858. CD002207.pub4 (CD002207).
33. Maurer, J., Harris, K.M., Issuance of patient reminders for influenza vaccination by US-based primary care physicians during the first year of universal influenza vaccination recommendations. Am. J. Public Health 104 (2014), e60–2.
34. McGinty, E.E., Goldman, H.H., Pescosolido, B., Barry, C.L., Portraying mental illness and drug addiction as treatable health conditions: effects of a randomized experiment on stigma and discrimination. Soc. Sci. Med. 126 (2015), 73–85.
35. Mendes, E., Americans’ Concerns About Obesity Soar, Surpass Smoking. 2012, Gallup News.
36. Morone, J.A., Ehlke, D., Health Politics and Policy. 5th ed., 2013, Cengage Learning, Stamford, CT.
37. National Center for Health Statistics, Number and Age-adjusted Rates of Drug-poisoning Deaths Involving Opioid Analgesics and Heroin: United States, 2000–2014. 2015 http://www.cdc.gov/nchs/data/health_policy/AADR_drug_poisoning_involving_OA_Heroin_US_2000-2014.pdf (accessed 07.01.16).
38. Office of National Drug Control Policy (ONDCP), 2013 National Drug Control Strategy (NDCS). 2013 http://www.whitehouse.gov/ondcp/national-drug-control-strategy (accessed 04.01.15).
39. Pescosolido, B., Martin, J., Long, J., Medina, T., Phelan, J., Link, B., A disease like any other? A decade of change in public reactions to schizophrenia, depression, and alcohol dependence. Am. J. Psychiatry 167 (2010), 1321–1330.
40. Rudd, R.A., Paulozzi, L.J., Bauer, M.J., Burleson, R.W., Carlson, R.E., Dao, D., Davis, J.W., Dudek, J., Eichler, B.A., Fernandes, J.C., Increases in heroin overdose deaths—28 states, 2010–2012. MMWR 63 (2014), 849–854.
41. Schwartz, R.P., Gryczynsi, J., O'Grady, K.E., Sharfstein, J.M., Warren, G., Olsen, Y., Mitchell, S.G., Jaffe, J.H., Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995–2009. Am. J. Public Health 103 (2013), 917–922.
42. StataCorp, Stata Statistical Software: Release 12. 2011, StataCorp LP, College Station, TX.
43. Thompson, T., Benz, J., Agiesta, J., Brewer, K.H., Bye, L., Obesity in the United States: Public Perceptions. 2013, The Associated Press, NORC Center for Public Research, Washington, DC.
44. Trust for America's Health, Prescription drug abuse: strategies to stop the epidemic, 2013. Trust For America's Health Report, 2013, Trust for America's Health, Washington, DC.
45. Turk, D., Dansie, E., Wilson, H., Moskovitz, B., Kim, M., Physicians’ beliefs and likelihood of prescribing opioid tamper-resistant formulations for chronic noncancer pain patients. Pain Med. 15 (2014), 625–636.
46. The U.S. Senate Committee on Finance, Baucus, Grassley Seek Answers About Opioid Manufacturers’ Ties to Medical Groups. Press Release. 2012 http://www.finance.senate.gov/newsroom/chairman/release/?id=021c94cd-b93e-4e4e-bcf4-7f4b9fae0047 (accessed 08.07.15).
47. Van Boekel, L.C., Brouwers, E.P.M., Van Weeghel, J., Garretsen, H.F.L., Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: dystematic review. Drug Alcohol Depend. 131 (2013), 23–35, 10.1016/j.drugalcdep.2013.02.018.
48. Van Zee, A., The promotion and marketing of OxyContin: commercial triump, public health tragedy. Am. J. Public Health 99 (2009), 221–227.
49. Volkow, N.D., McLellan, T.A., Cotto, J.H., Karithanom, M., Weiss, S.R.B., Characteristics of opioid prescriptions in 2009. JAMA 305 (2011), 1299–1301.
50. Weiner, B., Social Motivation, Justice And Themoral Emotions: An Attributional Approach. 2006, Lawrence Erlbaum, Mahwah, NJ.
51. Wheeler, E., Jones, T.S., Gilbert, M.K., Davidson, P.J., Opioid overdose prevention programs providing naloxone to laypersons—United States, 2014. MMWR 64 (2015), 631–635.
52. Wolfert, M.Z., Gilson, A.M., Dahl, J.L., Cleary, J.F., Opioid analgesics for pain control: wisconsin physicians’ knowledge, beliefs, attitudes, and prescribing practices. Pain Med. 11 (2010), 425–434, 10.1111/j.1526-4637.2009.00761.x.